Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Colman

Showing results (131-140 of 155) with videos related to

Pageof 16
Sort By:
Acta Neuropathologica|October 6, 2022
Molecular and clinicopathologic characteristics of gliomas with EP300::BCOR fusionsZhichao Wu, Sharika Rajan, Hye-Jung Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2017
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive GlioblastomaSara A Byron, Nhan L Tran, Rebecca F Halperin, et al.
Neuro-Oncology Advances|January 28, 2022
Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trialCorinne E Griguer, Claudia R Oliva, Christopher S Coffey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2026
Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Neuro-Oncology|April 17, 2018
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastomaBenjamin M Ellingson, Lauren E Abrey, Sarah J Nelson, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled TrialByram H Ozer, Scott M Lindhorst, Ryan T Merrell, et al.
Cancer Cell|September 3, 2013
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastomaKrishna P L Bhat, Veerakumar Balasubramaniyan, Brian Vaillant, et al.
Research Square|September 28, 2021
Impact of the COVID-19 pandemic on exercise habits among cancer patientsCaroline Himbert, Cassandra A Hathaway, Bailee Daniels, et al.
Nature Medicine|July 24, 2023
Correcting the drug development paradigm for glioblastoma requires serial tissue samplingKirit Singh, Kelly M Hotchkiss, Ian F Parney, et al.
Pageof 16

Showing results (131-140 of 155) with videos related to

Sort By:
Pageof 16
Acta Neuropathologica|October 6, 2022
Molecular and clinicopathologic characteristics of gliomas with EP300::BCOR fusionsZhichao Wu, Sharika Rajan, Hye-Jung Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2017
Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive GlioblastomaSara A Byron, Nhan L Tran, Rebecca F Halperin, et al.
Neuro-Oncology Advances|January 28, 2022
Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trialCorinne E Griguer, Claudia R Oliva, Christopher S Coffey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2026
Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform TrialPatrick Y Wen, Donald A Berry, Meredith B Buxton, et al.
Neuro-Oncology|April 17, 2018
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastomaBenjamin M Ellingson, Lauren E Abrey, Sarah J Nelson, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled TrialByram H Ozer, Scott M Lindhorst, Ryan T Merrell, et al.
Cancer Cell|September 3, 2013
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastomaKrishna P L Bhat, Veerakumar Balasubramaniyan, Brian Vaillant, et al.
Research Square|September 28, 2021
Impact of the COVID-19 pandemic on exercise habits among cancer patientsCaroline Himbert, Cassandra A Hathaway, Bailee Daniels, et al.
Nature Medicine|July 24, 2023
Correcting the drug development paradigm for glioblastoma requires serial tissue samplingKirit Singh, Kelly M Hotchkiss, Ian F Parney, et al.
Pageof 16